Fig. 1 · Structure

Documents & Downloads

Pantoprazole (Protonix)

Cat. No. A11696 CAS 102625-70-7

Proton Pump inhibitor

Pantoprazole is a proton pump inhibitor drug that inhibits gastric acid secretion.

In Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Cellular Effect

Cell Line Activity Value Description Reference
BXPC-3 IC50 18.51 μM Inhibition of survival of human BxPC3 cells after 10 to 14 days by crystal violet staining-based colony formation assay [PMID: 25513712]
HEK293 IC50 > 500 μM Inhibition of human MATE2K-mediated ASP+ uptake expressed in HEK293 cells after 1.5 mins by fluorescence assay [PMID: 23241029]
HEK293 IC50 > 500 μM Inhibition of human OCT1-mediated ASP+ uptake expressed in HEK293 cells after 3 mins by fluorescence assay [PMID: 23241029]
HEK293 IC50 1.5 μM Inhibition of human OCT2-mediated ASP+ uptake expressed in HEK293 cells after 3 mins by fluorescence assay [PMID: 23241029]
HEK293 IC50 137 μM Inhibition of human OCT3-mediated ASP+ uptake expressed in HEK293 cells after 3 mins by fluorescence assay [PMID: 23241029]
HEK293 IC50 2.8 μM Inhibition of human MATE1-mediated [14]-metformin uptake expressed in HEK293 cells after 1.5 mins by scintillation counting analysis [PMID: 23241029]
HEK293 IC50 43.2 μM Inhibition of human MATE2K-mediated ASP+ uptake expressed in HEK293 cells up to 500 uM after 1.5 mins by fluorescence assay [PMID: 23241029]
HEK293 IC50 43.2 μM Inhibition of human MATE1-mediated ASP+ uptake expressed in HEK293 cells after 1.5 mins by fluorescence assay [PMID: 23241029]
HEK-293T IC50 109 μM Inhibition of mouse Ido1 transfected in HEK293T cells using L-tryptophan as substrate assessed as kynurenine formation after 45 mins by spectrophotometric analysis [PMID: 23122865]
HEK-293T IC50 12.6 μM Inhibition of mouse Ido2 transfected in HEK293T cells using L-tryptophan as substrate assessed as kynurenine formation after 45 mins by spectrophotometric analysis [PMID: 23122865]
MDCK-II IC50 2.8 μM Inhibition of human MATE1-mediated [14]-metformin uptake expressed in polarized MDCK2 cells after 5 mins by liquid scintillation counting analysis [PMID: 23241029]

11 records · Scroll to view more

Pantoprazole (Protonix) Research Summary

This section summarizes 2 in vitro studies and 1 in vivo study of Pantoprazole (Protonix) from 2 published references. In vitro models include AGS cells; recombinant TOPK.

Pantoprazole (Protonix) In Vitro Studies

Pantoprazole treatment increased lysosome abundance in AGS cells compared with control cells. In a recombinant TOPK binding assay, Pantoprazole exhibited the lowest equilibrium dissociation constant. [1,2]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Pantoprazole and lysosome abundance in AGS cells

Cell-based study · AGS cells [1]

AGS cells received Pantoprazole at 120 μg/ml for 48 h under pH 7.4 conditions. Lysosome abundance increased compared with control cells.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
abundance of lysosomesReported result increased abundance of lysosomes in cells after PPI treatment compared with control cells[1]

Literature-Reported Treatment Conditions

Treatment concentration
120 μg/ml
Exposure duration
48 h in pH 7.4 condition
Vehicle
complete medium (CM)
Reported limits
Not stated in the sentences used: route.
Methods and source locations

Compound reported in the paper: Pantoprazole

Evidence for Pantoprazole as the sodium form reported in the paper, not the free base/neutral form supplied as A11696; no salt equivalence, dose conversion or lot validation.

Results > PPI-induced autophagosome formation via TM9SF4-mTOR pathway (S13, S14); Materials and methods > Cell viability assay and quantitative methods for drug interaction analysis (S164)

abundance of lysosomes: abundance of lysosomes; comparator: control cells — Results > PPI-induced autophagosome formation via TM9SF4-mTOR pathway (S14)

Pantoprazole binding to recombinant TOPK

Biochemical assay · Recombinant TOPK [2]

Recombinant TOPK was incubated with serially diluted Pantoprazole for 10 minutes at room temperature. Pantoprazole exhibited the lowest equilibrium dissociation constant, with a Kd of 24.2± 2.32 μM.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
binding affinity between the compounds and TOPKKd Kd of 24.2± 2.32 μM[2]

Literature-Reported Treatment Conditions

Treatment concentration
5mM pantoprazole as the highest concentration for the serial dilution
Exposure duration
10 minutes incubation at room temperature
Vehicle
ddH2O
Reported limits
Not stated in the sentences used: route.
Methods and source locations

Compound reported in the paper: Pantoprazole

Evidence for Pantoprazole as the sodium form reported in the paper, not the free base/neutral form supplied as A11696; no salt equivalence, dose conversion or lot validation.

RESULTS > Virtual ligand screening identifies the binding of pantoprazole to TOPK (S10, S12, S13); MATERIALS AND METHODS > Microscale thermophoresis (MST) (S59, S62, S63, S64)

binding affinity between the compounds and TOPK: binding affinity between the compounds and TOPK; comparator: HI-TOPK-032 — RESULTS > Virtual ligand screening identifies the binding of pantoprazole to TOPK (S10, S12)

Pantoprazole (Protonix) In Vivo Studies

Pantoprazole was administered by intraperitoneal injection to NOD-SCID mice injected with HCT 116 cells. Average tumor volume per mouse was lower in the Pantoprazole group compared with the vehicle group. [2]

Pantoprazole and tumor volume in NOD-SCID mice

Animal study · Non-obese Diabetic/Severe Combined Immunodeficiency (NOD-SCID) mice; HCT 116 cells; pantoprazole-treated group (n=8) [2]

NOD-SCID mice injected with HCT 116 cells received Pantoprazole at 100 mg/kg by intraperitoneal injection. On day 19, average tumor volume per mouse was 111mm3 in the Pantoprazole group compared with 285mm3 in the vehicle group.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
average tumor volume per mousetumor volume 111mm3[2]

Conditions shared by the study groups

Route
intraperitoneal (i.p.) injection
Treatment course
Treatment was started after two days of cells injection; every two days; 19 days
Vehicle
200 μl physiological saline
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Pantoprazole 100 mg/kg; 2.5 mg pantoprazolevehicle group (n=8)On day 19, the average tumor volume per mouse treated with 100 mg/kg pantoprazole was 111mm3 while that was 285mm3 in the vehicle group[2]
Pantoprazole 100 mg/kg; 2.5 mg pantoprazole
Model: Non-obese Diabetic/Severe Combined Immunodeficiency (NOD-SCID) mice; HCT 116 cells; pantoprazole-treated group (n=8)
Methods and source locations

Compound reported in the paper: Pantoprazole

Evidence for Pantoprazole as the sodium form reported in the paper, not the free base/neutral form supplied as A11696; no salt equivalence, dose conversion or lot validation.

RESULTS > Pantoprazole suppresses tumor growth by inhibiting TOPK activity in vivo (S42, S43); MATERIALS AND METHODS > In vivo xenograft mouse model (S98, S100, S102, S103, S104, S106)

average tumor volume per mouse: average tumor volume per mouse; comparator: vehicle group (n=8) — RESULTS > Pantoprazole suppresses tumor growth by inhibiting TOPK activity in vivo (S43)

Pantoprazole 100 mg/kg; 2.5 mg pantoprazole · RESULTS > Pantoprazole suppresses tumor growth by inhibiting TOPK activity in vivo (S43); MATERIALS AND METHODS > In vivo xenograft mouse model (S100, S103, S104, S106)

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 102625-70-7
Applications

Proton Pump inhibitor

Formula C16H15F2N3O4S
Molecular Weight 383.37
Synonyms Protonix
SMILES
COC1=C(C(=NC=C1)CS(=O)C2=NC3=C(N2)C=C(C=C3)OC(F)F)OC

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 74 mg/mL (193.02 mM)
Water Insoluble
Ethanol 74 mg/mL (193.02 mM)

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Pantoprazole (Protonix) Research References

  1. [1] Cao Y, Chen M, Tang D, et al. The proton pump inhibitor pantoprazole disrupts protein degradation systems and sensitizes cancer cells to death under various stresses. Cell Death Dis (2018). PMID: 29789637 DOI: 10.1038/s41419-018-0642-6 Source material
  2. [2] Zeng X, Liu L, Zheng M, et al. Pantoprazole, an FDA-approved proton-pump inhibitor, suppresses colorectal cancer growth by targeting T-cell-originated protein kinase. Oncotarget (2016). PMID: 26967058 DOI: 10.18632/oncotarget.7984 Source material

Added to your cart

View Cart Checkout
Loading...